Cybersecurity startup Cyera now valued at $6 billion
Why it matters Enterprise AI adoption is increasing data exposure risks.
Zoom in: Georgian, Greenoaks, and Lightspeed co-led the round, and were joined by insiders Accel, Coatue, Cyberstarts, Redpoint, Sapphire Ventures, Sequoia Capital, and Spark Capital.
Israel-based Cyera now has raised around $1.25 billion in total funding, including a $300 million Series D round last fall at a $3 billion valuation.
The bottom line: Pick an exit, any exit.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
an hour ago
- New York Post
Why top NYC restaurants are bringing in famed chefs from around the world
Top New York City restaurants are increasingly turning to collaborations with renowned chefs from around the globe to boost business and stand out from high-end rivals, Side Dish has learned. The collabs, while not a new phenomenon, have taken on added importance as President Trump's tariffs create challenges for chefs to source some of their favorite ingredients. However, importing talent from all corners of the globe – which at popular Tribeca haunt l'abeille means bringing in chefs from England, France, Belgium, Japan, Hong Kong and Thailand – remains tax-free. 7 l'abeille in Tribeca is importing talent from all corners of the globe. Eric Vitale Photography 'Global residences help everyone grow and learn — from the guests to the staff. They keep the restaurant interesting,' said Howard Chang, co-owner of Kuma Hospitality Group's l'abeille with partners Rahul Saito and executive chef Mitsunobu Nagae. The dinners these top chefs serve up at ticketed events aren't cheap. At a recent, prix-fixe collab dinner at l'abeille, Nagae worked with London-based chef Chet Sharma, who studied physics at Oxford and now helms the standout Indian-themed restaurant BiBi in London's swanky Mayfair neighborhood. The meal cost $325, with an additional $295 for wine pairings. The exclusive events, however, often don't bring in more money than regular a la carte dinners, restaurateurs told Side Dish. That's because the higher prices are offset by the cost of flying in the foreign-based chefs, along with some of their team members, and putting them all up in hotels. 7 Chet Sharma, left, and Mitsunobu Nagae collaborated on a prix-fixe dinner. Eric Vitale Photography 7 The collabs, while not a new phenomenon, have taken on added importance as President Trump's tariffs create challenges for chefs to source some of their favorite ingredients. Eric Vitale Photography The upside, they say, is that global collabs raise the restaurants' profiles, bring in new diners and offer educational benefits for staff. On the Upper East Side, Sushi Noz's executive chef Nozomu Abe is bringing in Michelin-starred Chef Endo Kazutoshi, a third-generation sushi master who trained in Japan before opening his namesake restaurant, Endo, at the Rotunda in London. 7 At Sushi Noz on the Upper East Side, executive chef Nozomu Abe, left, is bringing in Michelin-starred Chef Endo Kazutoshi. Hannah Wyatt Last week, the pair offered a rare collaborative omakase where they presented their culinary visions through the use of local fish and other influences. 'We started the Japan series in 2019,' said Hannah Wyatt, Sushi Noz's operations manager. 'Our goal was to showcase top chefs from Japan through collaborative dinners with chef Noz, with a focus on sushi and kaiseki chefs at the top of their respective fields.' In Williamsburg, Brooklyn, the owners of Layla's began bringing in chefs during COVID and continue to have pop-ups for 'brand exposure.' 7 The dinners these top chefs serve up at ticketed events aren't cheap. Eric Vitale Photography 7 The exclusive events, however, often don't bring in more money than regular a la carte dinners, restaurateurs told Side Dish. Eric Vitale Photography The most recent international collab involved chef Kyle Garry and chef Whyte Rushen of Whyte's in London, who is now on a 'worldwide' tour. 'We did it once, and it was really successful and fun and now it's something we try to do as often as we can,' Samuel Lynch, one of Layla's co-owners along with Stefano D'Orsogna and David Lacey, told Side Dish. The trend has even extended to the Hamptons, where Mavericks Montauk will welcome the crew from Michelin-starred Parisian restaurant Contraste on July 31. 7 The upside, they say, is that global collabs raise the restaurants' profiles, bring in new diners and offer educational benefits for staff. Interior of l'abeille, above. Eric Vitale Photography The collaboration was made possible by the deep-rooted friendship between Mavericks' pastry chef Remy Ertaud and Contraste's Louis De Vicari. We hear … that celeb chef Scott Conant is opening a posh new Italian restaurant, Leola, in the Bahamas at Baha Mar this fall. Leola will be on the casino level of Grand Hyatt Baha Mar, joining hotspots including Jon Batiste's Jazz Club, Marcus Samuelsson's Marcus at Baha Mar Fish + Chop House, Daniel Boulud's Cafe Boulud, and Dario Cecchini's Carna. The 8,800 square foot space comes with 106 seats in the main dining room and 130 seats outside. 'Bringing Leola to life at Baha Mar is something I've dreamed about for a long time,' Conant said. 'I've always been inspired by the beauty and spirit of the Bahamas, and it felt like the perfect place to create a restaurant that's both personal and inviting. With Leola, we're blending the kind of food and hospitality I love—warm, soulful, and rooted in connection.' Conant will also participate in the Fourth Annual Bahamas Culinary & Arts Festival, which runs from Oct. 22-26.
Axios
2 hours ago
- Axios
Exclusive: Embedded tax startup April raises $38M
April, an embedded tax platform, has raised $38 million in a Series B round led by QED Investors, founder Ben Borodach tells Axios exclusively. Why it matters: Embedding tax tools directly into financial apps can improve financial decision-making and boost customer retention. Zoom in: Nyca Partners and Team8 also participated in the Series B round, bringing the total funding April has raised to date to $78 million. How it works: Fintech apps and financial institutions use April's APIs to integrate tax filing and planning directly into their platforms, enabling year-round, real-time tax management. April operates on a SaaS-based model, offering flat-rate pricing to fintech partners, who can choose to mark up services for their end customers. "Our vision is to embed tax in every financial decision," Borodach says. "Taxes should be happening where you're managing your money. They should be happening in real time, and they should be personalized to you." Context: New York-based April operates in a market dominated by legacy tax-preparation giants like Intuit, H&R Block, Thomson Reuters, and Wolters Kluwer. But it recently became the first new company in 15 years to achieve national e-file coverage in all 50 states, Borodach says. The company has also launched a series of new products over the past year, including pro-assisted and pro-led tax filing, quarterly estimate tools for small business owners, and paycheck withholding optimizers. As a result, it is seeing increased demand from wealth management platforms, including integrations with digital advisers catering to mass-affluent clients and an upcoming partnership with a trillion-dollar asset manager. By the numbers: April claims it can reduce the time it takes to prepare and file taxes from the IRS' reported 13‑hour average down to just 22 minutes. The company processed hundreds of thousands of returns through partnerships with over 50 fintech apps and financial institutions this past tax season. It has seen its business grow three times year-to-date and more than seven times over the past 12 months, Borodach says. What's next: The company is preparing to launch advanced tax planning tools around capital gains, retirement planning, and stock transactions.
Forbes
4 hours ago
- Forbes
Israeli Startups Using AI To Accelerate Drug Discovery
AI Aiding in drug discovery Israel-based AION Labs wants to drive AI to revolutionize pharmaceutical drug discovery and development. AION is an innovative venture that brings together pharmaceutical heavyweights—Pfizer, AstraZeneca, Teva, and Merck—with entrepreneurial scientists, technology leaders, and successful investors. 'We are a venture studio that builds startups using computational technologies and artificial intelligence to unleash new capabilities to discover and develop new drugs with a venture model that we invented,' says Mati Gill, CEO of AION. This unique collaboration addresses a costly endeavor that is crucial to the quality of our lives. It takes $5 billion and ten years to bring a new drug to market. The world's top 20 pharmaceutical companies collectively spent $145 billion on R&D in 2022-23, according to a recent Deloitte report, which also noted 'AI is yet to become a 'game-changer' in pharma R&D.' A more comprehensive survey of 4,191 pharmaceutical companies worldwide, published in Nature Reviews Drug Discovery, found that they spent $276 billion on R&D in 2021. These R&D expenses have increased tenfold since the 1980s (after adjusting for inflation), and pharmaceutical companies now allocate approximately 25% of their revenue to R&D, nearly double the share seen in the early 2000s, according to CB Insights. 'AI could potentially cut years off the discovery process and compress clinical trial times by up to 30%. This would accelerate the delivery of new treatments to patients, unlock novel treatment approaches, and enable more personalized medicine,' noted CBI. Another CBI report, on the AI readiness of pharmaceutical companies, highlighted the importance of external collaboration, 'as breakthrough innovations increasingly emerge from partnerships rather than internal development alone.' Gill predicts that by 2030, the first truly AI-designed drugs will reach regulatory approval. He believes that Israel is uniquely positioned to be a leading ecosystem in transforming the global biotech and pharmaceutical landscape, given its strengths in multidisciplinary scientific discovery, entrepreneurial innovation, computational biology and big data analysis, as well as a robust and integrated healthcare system, and strong government support. 'For the first time, Israel's strengths are coinciding with what the future of the industry is going to be,' says Gill. There are three core principles behind every startup that AION selects and supports, explains Gill: they address a validated, well-defined, industry-wide problem statement; there's a multidisciplinary team that has expertise in both AI and biology and a technology that can solve that problem statement; and that at least one of AION' pharmaceutical partners is willing to commit to working with the startup to initially develop their technology and conduct with them a proof-of-concept at an early stage. The R&D teams of AION Labs' partners help select the specific industry-wide challenges to focus on and the technologies and scientist-led startups that will develop the solutions. To accomplish that, AION has established two tracks, one starting with the problem statement and the other starting with the technology. DenovAI is an example of starting with the problem statement. Is it possible to design proteins 'de novo' or completely from scratch? 'We ran a challenge and had 15 great candidates,' recounts Gill. 'We selected a senior scientist who had developed a technology called AlphaDesign that is basically doing the inverse of the famous AlphaFold.' The startup recently demonstrated its ability to generate new proteins with measurable, targeted function. Its AI-based platform for rapid de novo antibody discovery could reduce the discovery process from months to days, and broaden the scope of therapy to a wide range of diseases. Cassidy Bio is an example of starting with the technology. It is using large language models or LLMs to design new guide RNAs, unlocking the capability of gene therapy in a scalable and precise manner. Guide RNAs or gRNAs serve as the 'GPS' for CRISPR systems, directing the editing machinery to precise genetic targets. The design of gRNAs plays a critical role in determining both the efficacy and safety of gene-editing therapeutics. Professor Ayal Hendel of Israel's Bar-Ilan University, a leading expert in genome editing and gene therapy, teamed up with two experienced entrepreneurs to establish the startup. With AION Labs' help, they raised $8 million in seed funding and are working with AstraZeneca to validate their technology. Based on proprietary, clinically relevant genomic data generation, state-of-the-art predictive algorithms, and rigorous wet lab validation, Cassidy Bio is developing the first comprehensive predictive platform based on LLMs for gRNA design. Unlike the data driving AI consumer applications, which is mostly based on internet-scraped data, pharmaceutical data is proprietary data. AION Labs' unique collaborative model provides access to pharmaceutical firms' R&D teams and their data, along with a secure sharing environment facilitated by AION's tech partner, Amazon's cloud service. This means the pharmaceutical companies can share their proprietary data with the startups in AION Labs' portfolio, but not with each other. AION Labs is also a member of Israel's 8400 The Health Network. This network was founded in 2017 on the premise that HealthTech is Israel's next economic growth engine and that Israel has what it takes to become a game-changing player in the global HealthTech revolution, according to its CEO, Ari Strasberg. To date, the non-profit organization has developed numerous programs and national initiatives, ranging from HealthIL, which bridges the gap between healthcare systems and technology by facilitating over 1,300 pilots and implementing 160 projects, to Helix, which strengthens the working relationships between 46 top U.S. and Israeli HealthTech leaders. The organization has been very successful, says Strasberg, in creating a public-private partnership, connecting government programs with 'the needs of the ecosystem.' Another success story is the development of FIRE, the data interoperability standard used by the healthcare systems in Israel. Going forward, Strasberg would like 8400 to play a major role in increasing the number of very successful Israeli HealthTech startups. 'We have a few, but not enough,' says Strasberg. 'We need to have a few blockbuster ones that carry the entire ecosystem with them.'
